Meeting Banner
Abstract #1330

DCE-MRI in Patients with MRCC: Pilot Study Investigating Possible Biomarkers of Antiangiogenic Therapy

Andrew B. Gill1, Gayathri D S Anandappa2, Andrew N. Priest1, Andrew J. Patterson1, Martin J. Graves1, Ilse Joubert1, Louise M. Cookson3, Kate M. Fife2, Philip S. Murphy3, Duncan B. Richards3, Evis Sala1, Tim Eisen2, Duncan I. Jodrell2, David J. Lomas1

1Radiology, Addenbrooke's Hospital & University of Cambridge, Cambridge, United Kingdom; 2Oncology, Addenbrooke's Hospital & University of Cambridge; 3GlaxoSmithKline, United Kingdom

This study investigated DCE-MRI indices as early indicators of the activity of the antiangiogenic drug bevacizumab when used in patients with metastatic renal cell carcinoma. Two base-line and two post-treatment examinations were performed on six patients. DCE-MRI data was analysed using an extended Tofts kinetic model with a model AIF to produce parameter maps which were then analysed to yield tumour medians. Significant reductions, compared to the mean of the base-line levels, were found in Ktrans and vp in tumours 3 days after treatment. IAUGC90 values showed a significant decrease both 4 hours after treatment and 3 days after treatment.